High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: From clinical observation to evidence

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 1, 2016, Pages 73-82

  von Krogh, A S ^a,b   Quist Paulsen, P ^a,b   Waage, A ^a,b   Langseth, O O ^a   Thorstensen, K ^b   Brudevold, R ^c   Tjonnfjord G E ^d,e   Largiader C R ^f   Lammle B ^f,g   Kremer Hovinga, J A ^f  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c Møre and Romsdal Hospital Trust   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

^f UNIVERSITY OF BERN   (Switzerland)

^g UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

ADAMTS 13 protein, human; Congenital thrombotic thrombocytopenic purpura; Mutation; Prevalence study; Upshaw Schulman syndrome

Indexed keywords

VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAMTS13 PROTEIN, HUMAN;

ADAMTS13 GENE; ADULT; AGED; ARTICLE; BLOOD GROUP ABO SYSTEM; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GENE FREQUENCY; GENE MUTATION; HUMAN; INCIDENCE; INFANT; MALE; MIDDLE AGED; NORWAY; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; THROMBOTIC THROMBOCYTOPENIC PURPURA; YOUNG ADULT; ADOLESCENT; ALLELE; FAMILY HEALTH; GENETICS; GEOGRAPHY; HOMOZYGOTE; MUTATION; NEWBORN; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

ADAMTS13 PROTEIN; ADOLESCENT; ADULT; AGED; ALLELES; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FAMILY HEALTH; FEMALE; GENE FREQUENCY; GEOGRAPHY; HOMOZYGOTE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MUTATION; NORWAY; PREVALENCE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; YOUNG ADULT;

EID: 84955193592     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13186     Document Type: Article

References (40)

1. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600.
2. Reese JA, Muthurajah DS, Kremer Hovinga JA, Vesely SK, Terrell DR, George JN. Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer 2013; 60: 1676-82.
3. Galbusera M, Noris M, Remuzzi G. Inherited thrombotic thrombocytopenic purpura. Haematologica 2009; 94: 166-70.
4. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991; 325: 393-7.
5. Waage A, Siegel J, Thorstensen K, Lamvik J. Thrombotic thrombocytopenic purpura in 2 siblings: defective platelet function and plasma factor deficiency occurring simultaneously. Scand J Haematol. 1986; 36: 55-7.
6. Statistics Norway. Official statistics about Norwegian society since 1876. www.ssb.no. 2013. Accessed 14 April 2015.
7. Studt JD, Kremer Hovinga JA, Alberio L, Bianchi V, Lämmle B. von Willebrand factor-cleaving protease (ADAMTS-13) activity in thrombotic microangiopathies: diagnostic experience 2001/2002 of a single research laboratory. Swiss Med Wkly 2003; 133: 325-32.
8. Gulati S, Siebke E, Gamlem AM. A child with relapsing haemolytic anemia and thrombocytopenia. Tidsskr Nor Laegeforen 2007; 127: 884-5.
9. Assink K, Schiphorst R, Allford S, Karpman D, Etzioni A, Brichard B, van de Kar N, Monnens L, van den Heuvel L. Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency. Kidney Int 2003; 63: 1995-9.
10. Schneppenheim R, Budde U, Oyen F, Angerhaus D, Aumann V, Drewke E, Hassenpflug W, Haberle J, Kentouche K, Kohne E, Kurnik K, Mueller-Wiefel D, Obser T, Santer R, Sykora KW. von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP. Blood 2003; 101: 1845-50.
11. Holmen J, Midthjell K, Krüger O, Langhammer A, Holmen TL, Bratberg GH, Vatten L, Lund-Larsen PG. The Nord-Trøndelag Health Study 1995-97 (HUNT 2): objectives, contents, methods and participation. Norwegian Journal of Epidemiology (Norsk Epidemiologi). 2003; 13: 19-32.
12. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129: 93-100.
13. Froehlich-Zahnd R, George JN, Vesely SK, Terrell DR, Aboulfatova K, Dong JF, Luken BM, Voorberg J, Budde U, Sulzer I, Lämmle B, Kremer Hovinga JA. Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica 2012; 97: 297-303.
14. Kremer Hovinga JA, Mottini M, Lämmle B. Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods. J Thromb Haemost 2006; 4: 1146-8.
15. Kremer Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115: 1500-11.
16. Kornstad L. Frequency of the blood group antigen K and the A1A2BO groups in the Norwegian counties. Gene Geography: A Computerized Bulletin on Human Gene Frequencies. 1997; 11: 37-46.
17. Schneppenheim R, Kremer Hovinga JA, Becker T, Budde U, Karpman D, Brockhaus W, Hrachovinova I, Korczowski B, Oyen F, Rittich S, von Rosen J, Tjønnfjord GE, Pimanda JE, Wienker TF, Lämmle B. A common origin of the 4143insA ADAMTS13 mutation. Thromb Haemost 2006; 96: 3-6.
18. Lotta LA, Wu HM, Mackie IJ, Noris M, Veyradier A, Scully MA, Remuzzi G, Coppo P, Liesner R, Donadelli R, Loirat C, Gibbs RA, Horne A, Yang S, Garagiola I, Musallam KM, Peyvandi F. Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood 2012; 120: 440-8.
19. Fujimura Y, Matsumoto M. Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998-2008. Intern Med 2010; 49: 7-15.
20. Kokame K, Kokubo Y, Miyata T. Polymorphisms and mutations of ADAMTS13 in Japanese population and estimation of the number of patients with Upshaw-Schulman syndrome. J Thromb Haemost 2011; 9: 1654-6.
21. Scully M, Yarranton H, Liesner R, Cavenagh J, Hunt B, Benjamin S, Bevan D, Mackie I, Machin S. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol 2008; 142: 819-26.
22. Lotta LA, Garagiola I, Palla R, Cairo A, Peyvandi F. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat 2010; 31: 11-9.
23. Pimanda JE, Maekawa A, Wind T, Paxton J, Chesterman CN, Hogg PJ. Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13. Blood 2004; 103: 627-9.
24. Peyvandi F, Ferrari S, Lavoretano S, Canciani MT, Mannucci PM. von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. Br J Haematol 2004; 127: 433-9.
25. Manea M, Kristoffersson A, Tsai HM, Zhou W, Winqvist I, Oldaeus G, Billstrom R, Björk P, Holmberg L, Karpman D. ADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura. Eur J Pediatr 2007; 166: 249-57.
26. Cermakova Z, Hrdlikova R, Sulakova T, Koristka M, Kovarova P, Hrachovinova I. Thrombotic thrombocytopenic purpura: incidence of congenital form of disease in north Moravia (region Moravia-Silesia). Prague Med Rep. 2009; 110: 239-44.
27. Lindblom A, Thorsen S, Hillarp A, Björk P. Minor stroke as singular manifestation of hereditary thrombotic thrombocytopenic purpura in a young man. International Angiology: A Journal of the International Union of Angiology. 2009; 28: 336-9.
28. Klukowska A, Niewiadomska E, Budde U, Oyen F, Schneppenheim R. Difficulties in diagnosing congenital thrombotic thrombocytopenic purpura. J Pediatr Hematol Oncol 2010; 32: 103-7.
29. Donadelli R, Banterla F, Galbusera M, Capoferri C, Bucchioni S, Gastoldi S, Nosari S, Monteferrante G, Ruggeri ZM, Bresin E, Scheiflinger F, Rossi E, Martinez C, Coppo R, Remuzzi G, Noris M. In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. Thromb Haemost 2006; 96: 454-64.
30. Camilleri RS, Cohen H, Mackie IJ, Scully M, Starke RD, Crawley JT, Lane DA, Machin SJ. Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura. J Thromb Haemost 2008; 6: 331-8.
31. Tao Z, Anthony K, Peng Y, Choi H, Nolasco L, Rice L, Moake JL, Dong JF. Novel ADAMTS-13 mutations in an adult with delayed onset thrombotic thrombocytopenic purpura. J Thromb Haemost 2006; 4: 1931-5.
32. von Krogh AS, Kremer Hovinga JA, Tjønnfjord GE, Ringen IM, Lämmle B, Waage A, Quist-Paulsen P. The impact of congenital thrombotic thrombocytopenic purpura on pregnancy complications. Thromb Haemost 2014; 111: 1180-3.
33. de Vries PS, Boender J, Sonneveld MA, Rivadeneira F, Ikram MA, Rottensteiner H, Hofman A, Uitterlinden AG, Leebeek FW, Franco OH, Dehghan A, de Maat MP. Genetic variants in the ADAMTS13 and SUPT3H genes are associated with ADAMTS13 activity. Blood 2015; 125: 3949-55.
34. Bongard T. Life History Strategies, Mate Choice, and Parental Investment Among Norwegians Over a 300-Year Period. Dissertation Doctor Scientiarum. Department of Biology. Trondheim: Norwegian University of Science and Technology, 2005, 175.
35. Milman N, Pedersen P. Evidence that the Cys282Tyr mutation of the HFE gene originated from a population in Southern Scandinavia and spread with the Vikings. Clin Genet 2003; 64: 36-47.
36. Veyradier A, Lavergne JM, Ribba AS, Obert B, Loirat C, Meyer D, Girma JP. Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). J Thromb Haemost 2004; 2: 424-9.
37. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD Jr, Ginsburg D, Tsai HM. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-94.
38. Anstee DJ. The relationship between blood groups and disease. Blood 2010; 115: 4635-43.
39. Holmner A, Mackenzie A, Krengel U. Molecular basis of cholera blood-group dependence and implications for a world characterized by climate change. FEBS Lett 2010; 584: 2548-55.
40. Yamamoto F, Cid E, Yamamoto M, Blancher A. ABO research in the modern era of genomics. Transfus Med Rev 2012; 26: 103-18.